Rho, a full-service contract research organization, completed the acquisition of Dokumeds, a privately-held European CRO. Financial terms were not disclosed. “Our two companies are a great match, known for long-lasting relationships, scientific excellence and high-quality clinical development services. I’m thrilled to expand on our existing partnership and welcome Dokumeds to our company. Our teams are already aligned, ready to drive sponsors’ multinational programs forward to achieve development milestones and bring new and better treatments to patients. With this acquisition, Rho continues to offer focused therapeutic expertise as well as the attentiveness and agility of a medium-sized CRO, now with expanded global reach," Laura Helms Reece, Rho CEO.